Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 175

1.

Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).

Danchin N, Almahmeed W, Al-Rasadi K, Azuri J, Berrah A, Cuneo CA, Karpov Y, Kaul U, Kayıkçıoğlu M, Mitchenko O, Ruiz AJ, Aguilar Salinas CA, Santos RD, Mercier F, Blom D; ICLPS Investigators.

Eur J Prev Cardiol. 2018 Jan 1:2047487318777079. doi: 10.1177/2047487318777079. [Epub ahead of print]

PMID:
29771156
2.

A Pharmacogenetic Approach to the Treatment of Patients with PPARG Mutations.

Agostini M, Schoenmakers E, Beig J, Fairall L, Szatmari I, Rajanayagam O, Muskett FW, Adams C, Marais AD, O'Rahilly S, Semple RK, Nagy L, Majithia AR, Schwabe JWR, Blom DJ, Murphy R, Chatterjee K, Savage DB.

Diabetes. 2018 Apr 5. pii: db171236. doi: 10.2337/db17-1236. [Epub ahead of print]

PMID:
29622583
3.

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.

Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G.

Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):592-598. doi: 10.1161/ATVBAHA.117.310217. Epub 2017 Dec 28.

PMID:
29284604
4.

Ethylene Epoxidation Catalyzed by Ag Nanoparticles on Ag-LSX Zeolites formed by Pressure- and Temperature-Induced Auto-Reduction.

Kim D, Lee Y, Kim Y, Mingle K, Lauterbach J, Blom DA, Vogt T, Lee Y.

Chemistry. 2018 Jan 24;24(5):1041-1045. doi: 10.1002/chem.201704923. Epub 2018 Jan 12.

PMID:
29239500
5.

Effect of Evolocumab on Lipoprotein Particles.

Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, Elliott M, Davis M, Somaratne R, Preiss D.

Am J Cardiol. 2018 Feb 1;121(3):308-314. doi: 10.1016/j.amjcard.2017.10.028. Epub 2017 Nov 8.

PMID:
29221604
6.

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol.

Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, Raal FJ.

Eur Heart J. 2018 Apr 7;39(14):1162-1168. doi: 10.1093/eurheartj/ehx317.

PMID:
29106543
7.

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.

Sattar N, Toth PP, Blom DJ, Koren MJ, Soran H, Uhart M, Elliott M, Cyrille M, Somaratne R, Preiss D.

Am J Cardiol. 2017 Nov 1;120(9):1521-1527. doi: 10.1016/j.amjcard.2017.07.047. Epub 2017 Jul 31.

PMID:
28844508
8.

World Heart Federation Cholesterol Roadmap.

Murphy A, Faria-Neto JR, Al-Rasadi K, Blom D, Catapano A, Cuevas A, Lopez-Jimenez F, Perel P, Santos R, Sniderman A, Sy R, Watts GF, Zhao D, Yusuf S, Wood D.

Glob Heart. 2017 Sep;12(3):179-197.e5. doi: 10.1016/j.gheart.2017.03.002. Epub 2017 Jul 29.

PMID:
28765036
9.

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).

El Shahawy M, Cannon CP, Blom DJ, McKenney JM, Cariou B, Lecorps G, Pordy R, Chaudhari U, Colhoun HM.

Am J Cardiol. 2017 Sep 15;120(6):931-939. doi: 10.1016/j.amjcard.2017.06.023. Epub 2017 Jun 28.

10.

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia.

Blom DJ, Averna MR, Meagher EA, du Toit Theron H, Sirtori CR, Hegele RA, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Larrey D, Bloedon LT, Foulds P, Rader DJ, Cuchel M.

Circulation. 2017 Jul 18;136(3):332-335. doi: 10.1161/CIRCULATIONAHA.117.028208. No abstract available.

PMID:
28716835
11.

Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.

Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, Khovidhunkit W, Dufour R, Garg A, McMahon MA, Pullinger CR, Sandoval NP, Hu X, Allan CM, Larsson M, Machida T, Murakami M, Reue K, Tontonoz P, Goldberg IJ, Moulin P, Charrière S, Fong LG, Nakajima K, Young SG.

N Engl J Med. 2017 Apr 27;376(17):1647-1658. doi: 10.1056/NEJMoa1611930. Epub 2017 Apr 5.

12.

Modifiable Risk Factors for the Spread of Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Among Long-Term Acute-Care Hospital Patients.

Okamoto K, Lin MY, Haverkate M, Lolans K, Moore NM, Weiner S, Lyles RD, Blom D, Rhee Y, Kemble S, Fogg L, Hines DW, Weinstein RA, Hayden MK.

Infect Control Hosp Epidemiol. 2017 Jun;38(6):670-677. doi: 10.1017/ice.2017.62. Epub 2017 Apr 11.

PMID:
28397615
13.

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.

Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA.

Lancet Diabetes Endocrinol. 2017 Apr;5(4):280-290. doi: 10.1016/S2213-8587(17)30044-X. Epub 2017 Feb 16.

PMID:
28215937
14.

The Composer's Program Note for Newly Written Classical Music: Content and Intentions.

Blom DM, Bennett D, Stevenson I.

Front Psychol. 2016 Nov 9;7:1707. eCollection 2016.

15.

Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).

Gibbs JP, Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, Gibbs MA, Somaratne R, Wasserman SM, Blom D.

J Clin Pharmacol. 2017 May;57(5):616-626. doi: 10.1002/jcph.840. Epub 2016 Nov 15.

16.

Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease.

Ross IL, Lacerda M, Pillay TS, Blom DJ, Johannsson G, Dave JA, Levitt NS, Haarburger D, van der Walt JS.

Horm Metab Res. 2016 Dec;48(12):814-821. Epub 2016 Nov 3.

PMID:
27813051
17.

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.

Villard EF, Thedrez A, Blankenstein J, Croyal M, Tran TT, Poirier B, Le Bail JC, Illiano S, Nobécourt E, Krempf M, Blom DJ, Marais AD, Janiak P, Muslin AJ, Guillot E, Lambert G.

JACC Basic Transl Sci. 2016 Oct;1(6):419-427. doi: 10.1016/j.jacbts.2016.06.006.

18.

Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.

Blom DJ, Koren MJ, Roth E, Monsalvo ML, Djedjos CS, Nelson P, Elliott M, Wasserman SM, Ballantyne CM, Holman RR.

Diabetes Obes Metab. 2017 Jan;19(1):98-107. doi: 10.1111/dom.12788. Epub 2016 Oct 14.

PMID:
27619750
19.

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.

Blom DJ, Dent R, Castro RC, Toth PP.

Vasc Health Risk Manag. 2016 May 9;12:185-97. doi: 10.2147/VHRM.S102564. eCollection 2016. Review.

20.

Recurrent coma and fever in familial hemiplegic migraine type 2. A prospective 15-year follow-up of a large family with a novel ATP1A2 mutation.

Pelzer N, Blom DE, Stam AH, Vijfhuizen LS, Hageman A, van Vliet JA, Ferrari MD, van den Maagdenberg A, Haan J, Terwindt GM.

Cephalalgia. 2017 Jul;37(8):737-755. doi: 10.1177/0333102416651284. Epub 2016 May 24.

PMID:
27226003

Supplemental Content

Loading ...
Support Center